文献速递造血干细胞移植与细胞治疗

定义慢性移植物抗宿主病中致病性IL-17和CSF-1基因表达特征

Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease.
PubMed 文献 · Blood · 2025-01-01

该研究利用单细胞测序在小鼠慢性移植物抗宿主病(cGVHD)模型中反向工程出血液中IL-17和CSF-1的时间性特征,并在70%的cGVHD诊断时患者及一半移植后第+100天后续发生cGVHD的患者单核细胞中鉴定出相应特征。这些特征可在临床研究中前瞻性评估,以区分靶向这些通路的潜在应答者与无应答者。

要点

  • 小鼠cGVHD模型单细胞测序定义出血液单核细胞中独特的IL-17和CSF-1特征。
  • 70%的cGVHD诊断时患者和半数移植后第+100天后续发生cGVHD的患者中可鉴定出这些特征。
  • 这些特征可在临床研究中前瞻性评估,以帮助区分靶向这些通路的潜在应答者与无应答者。

核心结论

  • 在小鼠cGVHD模型中反向工程出的IL-17和CSF-1血液单核细胞特征,可在70%的cGVHD诊断时患者及半数移植后第+100天后续发生cGVHD的患者中鉴定出。
  • 这些特征可在临床研究中前瞻性评估,以帮助区分靶向这些通路的潜在应答者与无应答者。

研究设计与样本

  • 研究使用单细胞测序方法在临床前cGVHD小鼠模型中反向工程血液中IL-17和CSF-1的时间性特征,并用其 interrogate 患者。

主要发现

  • 在小鼠血液单核细胞中定义了独特的、非直觉的IL-17和CSF-1特征。
  • 这些特征可在70%的cGVHD诊断时患者的相关单核细胞群中鉴定出。
  • 这些特征可在半数移植后第+100天后续发生cGVHD的患者中鉴定出。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) remains the leading cause of nonrelapse morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Effective therapeutic agents targeting dysregulated cytokines including interleukin-17 (IL-17) and colony-stimulating factor 1 (CSF-1) have been defined in preclinical models of cGVHD, and efficacy in subsequent clinical trials has led to their recent US Food and Drug Administration approval. Despite this, these agents are effective in only a subset of patients, expensive, difficult to access outside the United States, and used in a trial-and-error fashion. The ability to readily discern druggable, dysregulated immunity in these patients is desperately needed to facilitate the selection of appropriate treatment and to potentially identify high-risk individuals for preemptive therapy. We used single-cell sequencing-based approaches in our informative preclinical cGVHD models to "reverse engineer" temporal IL-17 and CSF-1 signatures in mouse blood that could be used to interrogate patients. We defined distinct, nonintuitive IL-17 and CSF-1 signatures in mouse blood monocytes that could be identified in relevant monocyte populations within 70% of patients at diagnosis of cGVHD and in half of patients at day +100 after HCT who subsequently developed cGVHD. These signatures can now be evaluated prospectively in clinical studies to help delineate potential responder and nonresponders to relevant therapeutics targeting these pathways.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Boiko JR, Ensbey KS, Waltner OG, et al. Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease. Blood. 2025. PMID: 39977705. doi:10.1182/blood.2024025337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。